BUZZ-Eton Pharma falls after co licenses rare disease drug to Spanish company

Reuters2025-04-01
BUZZ-Eton Pharma falls after co licenses rare disease drug to Spanish company

** Shares of drug developer Eton Pharmaceuticals ETON.O fall ~3% to $12.58

** ETON says it has out-licensed the non-U.S. commercial rights for its rare disease drug, Increlex, to Spain's Esteve Pharmaceuticals

** Esteve will pay Eton 4 million euros ($4.32 million) upfront for the licensing rights lasting up to ten years

** ETON will still make the product and sell it to Esteve at a fixed price

** Esteve also receives an option to permanently acquire the international rights in the future for up to 6 million euros

** Increlex is used to treat growth failure in children and adolescents with severe primary insulin-like growth factor-1 deficiency

** Including session move, ETON fell 2.6% YTD

($1 = 0.9267 euros)

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment